Health Care

Vaxart’s oral flu vaccine breakthrough: gut‑stimulated immunity, rising Nasdaq returns, and a $124 M biotech leader poised to reshape global vaccine delivery.

Insmed (INSM) faces short‑term hurdles amid promising long‑term biotech growth, with a robust rare‑disease pipeline and strategic partnerships driving investor interest.

ADMA Biologics to host its 42nd AGM via video on Sept. 25, 2026—shareholders can access the FY 25‑26 report, vote electronically, and join leaders for a transparent discussion on future growth.

Butterfly Network’s AI‑powered, cloud‑enabled portable ultrasound devices are revolutionizing medical imaging, making high‑quality diagnostics accessible worldwide.

Alnylam’s RNA‑i tech shows promise in cardiology, yet mixed trial data and stiff PCSK9 competition keep investors on watch‑for‑Phase‑3 approvals.

Avricore Health’s HealthTab launch into 100 UK pharmacies signals a bold move from niche Canadian distributor to a major OTC player, offering investors fresh growth potential.

Explore STABLECOIN DEVELOPMENT CORP’s latest stock snapshot, $0.86 closing price, 52‑week range, $25.59M market cap, and niche anti‑infective pharma focus.

Argenx SE fuels growth with AI‑driven BenchSci partnership, 18‑quarter sales momentum, and active investor outreach—pioneering next‑gen antibody therapies.

Medicenna Therapeutics targets CNS and urological cancers with immuno‑oncology breakthroughs, navigating volatile biotech markets while aiming to transform patient care.

Biogen’s surge: new immunology wins, zorevunersen’s 4‑year epilepsy breakthrough and Canada’s LEQEMBI reimbursement boost diversified revenue, premium pricing, and future growth.